STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Janus Henderson Entities Report 10% and 5% Holdings in ICU Medical

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Janus Henderson Group plc and an affiliated fund reported beneficial ownership stakes in ICU Medical, Inc. Janus Henderson Group plc is shown with shared voting and dispositive power over 2,470,146 common shares, equal to 10.0% of the class. Janus Henderson Enterprise Fund reports shared voting and dispositive power over 1,230,753 shares, equal to 5.0% of the class. The filing also notes that JHIUS may be deemed beneficial owner of 2,411,637 shares ( 9.8% ) with shared voting and dispositive authority.

The filing includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control. Power of attorney and signature attestations are included, identifying the compliance officer who signed on behalf of the reporting entities.

Positive

  • Janus Henderson Group plc reports a material 10.0% stake in ICU Medical (2,470,146 shares), indicating significant institutional investment
  • Janus Henderson Enterprise Fund holds 5.0% (1,230,753 shares), showing multiple affiliated vehicles with substantial positions

Negative

  • None.

Insights

TL;DR: Institutional investor Janus Henderson discloses a material stake (10.0%) in ICUI; multiple affiliated vehicles hold additional positions.

Janus Henderson Group plc's disclosed 10.0% ownership (2,470,146 shares) is a material, reportable position that can influence market perception of ICU Medical's shareholder base and free float. The separate disclosure that JHIUS may be deemed to hold 2,411,637 shares (9.8%) and that the Enterprise Fund holds 1,230,753 shares (5.0%) highlights multiple affiliated reporting persons with overlapping shared voting and dispositive power. This is a routine Section 13G/A ownership disclosure rather than an explicit activist move; the certification states holdings are in the ordinary course of business.

TL;DR: Disclosure shows significant institutional ownership but affirms no stated intent to change control; governance implications depend on future actions.

The schedule documents shared voting and dispositive authority among Janus Henderson entities for positions at or above the 5% reporting threshold, including a 10.0% stake by the parent reporting entity. While a 10% stake is large enough to draw attention from management and other shareholders, the filing's certification indicates the stake is held in the ordinary course and not for control purposes. Governance impact will hinge on whether Janus Henderson exercises its shared voting power actively or files additional, more assertive disclosures.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



JANUS HENDERSON GROUP PLC
Signature:Kristin Mariani
Name/Title:Head of North America Compliance, CCO
Date:08/14/2025
Janus Henderson Enterprise Fund
Signature:Kristin Mariani
Name/Title:Head of North America Compliance, CCO
Date:08/14/2025
Exhibit Information

POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

FAQ

How many ICUI shares does Janus Henderson Group plc report owning?

The filing reports Janus Henderson Group plc has shared voting and dispositive power over 2,470,146 shares, representing 10.0% of the class.

What stake does Janus Henderson Enterprise Fund report in ICUI?

Janus Henderson Enterprise Fund reports shared voting and dispositive power over 1,230,753 shares, equal to 5.0% of the class.

Does the filing state whether these holdings aim to influence control of ICU Medical (ICUI)?

The filing includes a certification that the securities are held in the ordinary course of business and were not acquired to change or influence control.

Is there any subsidiary or affiliate identified as relevant to these holdings?

The filing identifies indirect subsidiaries (e.g., JHIUS, JHIUKL, JHIAIFML) as registered investment advisers furnishing advice to managed portfolios and notes JHIUS may be deemed beneficial owner of 2,411,637 shares (9.8%).

Who signed the Schedule 13G/A on behalf of the reporting entities?

The filing was signed by Kristin Mariani, Head of North America Compliance, CCO, on behalf of the reporting entities.
Icu Medical

NASDAQ:ICUI

ICUI Rankings

ICUI Latest News

ICUI Latest SEC Filings

ICUI Stock Data

3.52B
23.98M
3.14%
113.48%
5.47%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
SAN CLEMENTE